{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:29:59Z","timestamp":1790310599558,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T00:00:00Z","timestamp":1414368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2490-14-84","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T14:02:40Z","timestamp":1414418560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tolterodine extended release in the treatment of male oab\/storage luts: a systematic review"],"prefix":"10.1186","volume":"14","author":[{"given":"Mauro","family":"Gacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Novara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"De Nunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Brunocilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Sebastianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Serni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"issue":"6","key":"377_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","volume":"44","author":"R Rosen","year":"2003","unstructured":"Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Chris R, Giuliano F: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003, 44 (6): 637-649.","journal-title":"Eur Urol"},{"key":"377_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A, Standardisation\u00a0Sub-Committee\u00a0of the\u00a0International\u00a0Continence\u00a0Society: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003, 61: 37-49.","journal-title":"Urology"},{"issue":"3","key":"377_CR3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol. 1984, 132 (3): 474-479.","journal-title":"J Urol"},{"issue":"4","key":"377_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.eururo.2013.04.042","volume":"64","author":"R Soler","year":"2013","unstructured":"Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Drake MJ, Gratzke C, Lee R, Cruz F: Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013, 64 (4): 610-621.","journal-title":"Eur Urol"},{"key":"377_CR5","first-page":"1283","volume":"94","author":"ME Laniado","year":"2004","unstructured":"Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter SS: Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinarysymptoms. BJ UInt. 2004, 94: 1283-1286.","journal-title":"BJ UInt"},{"key":"377_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006, 50: 1306-1315.","journal-title":"Eur Urol"},{"key":"377_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1368-5031.2005.00617.x","volume":"59","author":"F Haab","year":"2005","unstructured":"Haab F, Castro-Diaz D: Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005, 59: 931-937.","journal-title":"Int J Clin Pract"},{"key":"377_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00345-009-0446-5","volume":"27","author":"MC Michel","year":"2009","unstructured":"Michel MC, Chapple CR: Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol. 2009, 27: 705-709.","journal-title":"World J Urol"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","volume":"54","author":"M Oelke","year":"2008","unstructured":"Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, H\u00f6fner K: Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008, 54: 419-426.","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"377_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","volume":"188","author":"EA Gormley","year":"2012","unstructured":"Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE, Scarpero HM, Tessier CD, Vasavada SP, American Urological Association: Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. J Urol. 2012, 188 (6 Suppl): 2455-2463.","journal-title":"J Urol"},{"issue":"2","key":"377_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/nau.20208","volume":"25","author":"K De Laet","year":"2006","unstructured":"De Laet K, De Watcher S, Wyndaele JJ: Systemic oxybutinin decreases afferent activity of the pelvic nerve of the rat: new insight into the working mechanism of antimuscarinics. Neururol Urodyn. 2006, 25 (2): 156-","journal-title":"Neururol Urodyn"},{"key":"377_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","volume":"6","author":"YE Yarker","year":"1995","unstructured":"Yarker YE, Goa KL, Fitton A: Oxybutynin: A review of its pharmacodynamics and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995, 6: 243-246.","journal-title":"Drugs Aging"},{"key":"377_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0302-2838(01)00009-4","volume":"41","author":"ES Rovner","year":"2002","unstructured":"Rovner ES, Wein AJ: Once daily, extended release formulations of antimuscarinics agents in the treatment of overactive bladder: A review. Eur Urol. 2002, 41: 6-14.","journal-title":"Eur Urol"},{"key":"377_CR14","first-page":"191","volume":"4","author":"D Ulahannan","year":"2009","unstructured":"Ulahannan D, Wagg A: The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009, 4: 191-196.","journal-title":"Clin Interv Aging"},{"key":"377_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/nau.1930140606","volume":"14","author":"MMS Stahl","year":"1995","unstructured":"Stahl MMS, Ekstr\u00f6m B, Sparf B, Mattiasson A, Andersson K-E: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn. 1995, 14: 647-655.","journal-title":"Neurourol Urodyn"},{"key":"377_CR16","first-page":"287","volume":"35","author":"N Brynne","year":"1997","unstructured":"Brynne N, Stahl MMS, Hall\u00e9n BH, Edlund PO, Palm\u00e9r L, H\u00f6glund P, Gabrielsson J: Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Therap. 1997, 35: 287-295.","journal-title":"Int J Clin Pharmacol Therap"},{"issue":"22\u201323","key":"377_CR17","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0024-3205(01)01051-7","volume":"68","author":"L Nilvebrant","year":"2001","unstructured":"Nilvebrant L: Clinical experiences with tolterodine. Life Sci. 2001, 68 (22\u201323): 2549-2556.","journal-title":"Life Sci"},{"key":"377_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","volume":"54","author":"G Novara","year":"2008","unstructured":"Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V, Artibani W: A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008, 54: 740-763.","journal-title":"Eur Urol"},{"key":"377_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1464-410X.1994.tb07477.x","volume":"73","author":"CR Chapple","year":"1994","unstructured":"Chapple CR, Smith D: The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol. 1994, 73: 117-123.","journal-title":"Br J Urol"},{"key":"377_CR20","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","volume":"169","author":"A Athanasopoulos","year":"2003","unstructured":"Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003, 169: 2253-2256.","journal-title":"J Urol"},{"key":"377_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N\u2019Dow J, Nordling J, de la Rosette JJ: Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS) incl. Benign Prostatic Obstruction (BPO). Eur Urol. 2013, 64: 118-140.","journal-title":"Eur Urol"},{"key":"377_CR22","volume-title":"AUA Guidelines: Management of BPH, Revision","author":"KT McVary","year":"2010","unstructured":"McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC: AUA Guidelines: Management of BPH, Revision. 2010"},{"issue":"4","key":"377_CR23","first-page":"289","volume":"26","author":"H Postlind","year":"1998","unstructured":"Postlind H, Danielson A, Lindgren A, Andersson SH: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998, 26 (4): 289-293.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"377_CR24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","volume":"53","author":"G Larsson","year":"1999","unstructured":"Larsson G, Hall\u00e9n B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 1999, 53 (5): 990-998.","journal-title":"Urology"},{"issue":"2\u20133","key":"377_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","volume":"327","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B: Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997, 327 (2\u20133): 195-207.","journal-title":"Eur J Pharmacol"},{"issue":"13\u201314","key":"377_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","volume":"60","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Hall\u00e9n B, Larsson G: Tolterodine: a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997, 60 (13\u201314): 1129-1136.","journal-title":"Life Sci"},{"issue":"3","key":"377_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B Olsson","year":"2001","unstructured":"Olsson B, Szamosi J: Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine. Clinical Pharmacokinetics. 2001, 40 (3): 227-235.","journal-title":"Clinical Pharmacokinetics"},{"key":"377_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1074248408325404","volume":"13","author":"B Olshansky","year":"2008","unstructured":"Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L: Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants\u2009>\u2009or\u2009=\u200950\u00a0years. J Cardiovas Pharmacol Ther. 2008, 13: 241-251.","journal-title":"J Cardiovas Pharmacol Ther"},{"issue":"5","key":"377_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","volume":"63","author":"N Brynne","year":"1998","unstructured":"Brynne N, Dal\u00e9n P, Alv\u00e1n G, Bertilsson L, Gabrielsson J: Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998, 63 (5): 529-539.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"377_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00002512-200118040-00005","volume":"18","author":"D Clemett","year":"2001","unstructured":"Clemett D, Jarvis B: Tolterodine. Drugs Aging. 2001, 18 (4): 277-304.","journal-title":"Drugs Aging"},{"issue":"6","key":"377_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","volume":"49","author":"JG Malone-Lee","year":"2001","unstructured":"Malone-Lee JG, Walsh JB, Maugourd MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001, 49 (6): 700-705.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"377_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appel","year":"1997","unstructured":"Appel RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysisi. Urology. 1997, 50 (6): 90-96.","journal-title":"Urology"},{"key":"377_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","volume":"8","author":"P Abrams","year":"1998","unstructured":"Abrams P, Freeman R, Anderstrom C, Revicki D, Stewart W, Coprey R: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutinin in patients with overactive bladder. Br J Urol. 1998, 8: 801-810.","journal-title":"Br J Urol"},{"key":"377_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s001929970003","volume":"10","author":"HP Drutz","year":"1999","unstructured":"Drutz HP, Appel R, Gleason D, Klimberg I, Radomski S: Clinical efficacy and safety of tolterodine comnpared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J. 1999, 10: 283-289.","journal-title":"Int Urogynecol J"},{"key":"377_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ucl.2006.06.004","volume":"33","author":"JA Kanoksky","year":"2006","unstructured":"Kanoksky JA, Nitti VW: Tolterodine for treatment of overactive bladder. Urol Clin N Am. 2006, 33: 447-453.","journal-title":"Urol Clin N Am"},{"issue":"3","key":"377_CR36","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P Van Kerrebroeck","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolterodine Study Group: Tolterodine once-daily: superior effi cacy and tolerability in the treatment of the overactive bladder. Urology. 2001, 57 (3): 414-421.","journal-title":"Urology"},{"key":"377_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2013.01.018","volume":"64","author":"C Fullhase","year":"2013","unstructured":"Fullhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, Marberger M, Montorsi F, Novara G, Oelke M, Porst H, Roehrborn C, Stief C, McVary KT: Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol. 2013, 64: 228-243.","journal-title":"Eur Urol"},{"key":"377_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","volume":"56","author":"C Chapple","year":"2009","unstructured":"Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol. 2009, 56: 534-543.","journal-title":"Eur Urol"},{"key":"377_CR39","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006, 296: 2319-2328.","journal-title":"JAMA"},{"issue":"5","key":"377_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.urology.2009.12.010","volume":"75","author":"DE Chung","year":"2010","unstructured":"Chung DE, Te AE, Staskin DR, Kaplan SA: Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010, 75 (5): 1144-1148.","journal-title":"Urology"},{"issue":"1","key":"377_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","volume":"60","author":"A Athanasopoulosa","year":"2011","unstructured":"Athanasopoulosa A, Chapple C, Fowler C, Gratzke C, Kaplan S, Stief C, Tubaro A: The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. Eur Urol. 2011, 60 (1): 94-105.","journal-title":"Eur Urol"},{"key":"377_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"V Nitti","year":"2013","unstructured":"Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S: Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013, 189: 1388-1395.","journal-title":"J Urol"},{"issue":"7","key":"377_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE: Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013, 67 (7): 619-632.","journal-title":"Int J Clin Pract"},{"key":"377_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"AC Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH, OPERA Study Group: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003, 78: 687-695.","journal-title":"Mayo Clin Proc"},{"key":"377_CR45","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005, 48: 464-470. overactive bladder syndrome: results of the STAR trial. Eur Urol 2005, 48:464\u201370","journal-title":"Eur Urol"},{"key":"377_CR46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","volume":"52","author":"C Chapple","year":"2007","unstructured":"Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007, 52: 1204-1212. Corrigendum. Eur Urol 2008, 53:1319","journal-title":"Eur Urol"},{"key":"377_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bju.12174","volume":"112","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL: Efficacy of fesoterodine compared to extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013, 112: 373-385.","journal-title":"BJU Int"},{"issue":"3","key":"377_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2010.11.021","volume":"59","author":"JW Th\u00fcroff","year":"2011","unstructured":"Th\u00fcroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schr\u00f6der A, Tubaro A: EAU guidelines on urinary incontinence. Eur Urol. 2011, 59 (3): 387-400.","journal-title":"Eur Urol"},{"key":"377_CR49","first-page":"49","volume-title":"Guidelines on urinary incontinence","author":"MG Lucas","year":"2013","unstructured":"Lucas MG, Bedretdinova D, Bosch JLHR, Burkhard F, Cruz F, Nambiar AK, de Ridder DJKM, Tubaro A, Pickard RS: Guidelines on urinary incontinence. 2013, Arnhem (The Netherlands): European Association of Urology (EAU), 49-65."},{"issue":"6","key":"377_CR50","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","volume":"62","author":"N Buser","year":"2012","unstructured":"Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM: Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012, 62 (6): 1040-1060.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-14-84\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-84","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-14-84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T15:19:07Z","timestamp":1548083947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-14-84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,27]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-14-84","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,27]]},"assertion":[{"value":"18 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"84"}}